2021 FAQs – FACTS about Atypical HUS
aHUS Awareness Day 2021 - Answers to FAQs Finding information about any rare disease is challenging, and perhaps more so for…
Withdrawal – need for a consensus
Article No. 457 Yet another article about the outcome of withdrawal of eculizumab treatment has appeared. It is not about a…
aHUS PREGNANCY COUNSELLING
Article No. 454 aHUS triggered by pregnancy is relatively common and accounts for 16% of female ( 18 to 45 years)…
aHUS nomenclature project group
Article No. 451 4 August 2021 Following on swiftly from Article No. 450 about the current babble of names and need…
What became of the aHUS 130?
Article No. 446 14 July 2021 Eculizumab effectiveness and safety in the treatment of aHUS was established in five clinical trials…
aHUS Trials Watch 12a (crovalimab)
Article No. 445 13 July 2021 Hoffmann Roche has announced its pediatric trial of crovalimab for aHUS. It is featured on…
COVID 19 triggers aHUS
Article No. 444 12 July 2021 Not unexpectedly, as aHUS Global Action had postulated it in March last year, a COVID…
Evaluating ravulizumab for aHUS treatment
Article No. 442 23 June 2021 Today NICE ( The National Institute for Health and Care Excellence) concluded its evaluation of…
aHUS Trial Watch 12 (crovalimab update)
Article No. 432 7 May 2021 In the past week or so, the possible trial of a new technology for treating…
- Go to the previous page
- 1
- …
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- …
- 31
- Go to the next page